Last reviewed · How we verify
Eledone Peptide — Competitive Intelligence Brief
phase 2
Neuromedin-K receptor
Neuroscience
Recombinant protein
Live · refreshed every 30 min
Target snapshot
Eledone Peptide (ELEDOISIN). Eledoisin works by binding to the Neuromedin-K receptor, which is involved in various physiological processes.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Eledone Peptide TARGET | ELEDOISIN | phase 2 | Neuromedin-K receptor | |||
| Veozah | FEZOLINETANT | Astellas Pharma | marketed | Neurokinin 3 Receptor Antagonist [EPC] | Neuromedin-K receptor | 2023-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Eledone Peptide CI watch — RSS
- Eledone Peptide CI watch — Atom
- Eledone Peptide CI watch — JSON
- Eledone Peptide alone — RSS
Cite this brief
Drug Landscape (2026). Eledone Peptide — Competitive Intelligence Brief. https://druglandscape.com/ci/eledoisin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing